Home › Plasma Cell Leukemia
Pag-aaral pangklinika para sa Plasma Cell Leukemia na nagre-recruit sa U.S.
8 pag-aaral para sa Plasma Cell Leukemia ang nagre-recruit ng mga kalahok sa mga site sa buong Estados Unidos.
Mga lungsod na may pinakamaraming pag-aaral
Ayos sa estado
Mga pag-aaral na kamakailan lamang in-update
Opisyal na teksto ng pag-aaral (English)
Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial
Nagre-recruitPhase 2
Edad 18 hanggang 80 · Lahat ng kasarian · Na-update Set 29, 2026 · NCT07605416Use of Isatuximab, Dexamethasone and Lenalidomide in a Go-Slow Fashion for Ultra-Frail Patients With Multiple Myeloma
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 11, 2026 · NCT06517017Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
Nagre-recruitPhase 1/2
Edad 12 hanggang 80 · Lahat ng kasarian · Na-update Ago 7, 2026 · NCT05092451Allo HSCT Using RIC and PTCy for Hematological Diseases
Nagre-recruitPhase 2
Hanggang edad 75 · Lahat ng kasarian · Na-update Hul 6, 2026 · NCT05805605Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
Nagre-recruitPhase 2
Hanggang edad 60 · Lahat ng kasarian · Na-update Hun 25, 2026 · NCT03314974Impact of Budesonide on Incidence of ≥ Gr2 Diarrhea in Multiple Myeloma (MM) Patients Undergoing Autologous Stem Cell Transplant
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Hun 5, 2026 · NCT05405387Cancer and Aging Resilience Evaluation in Older Adults With Hematologic Malignancies: The CARE-Heme Registry
Nagre-recruitObservasyonal na pag-aaral
Edad 50 pataas · Lahat ng kasarian · Na-update Dis 8, 2025 · NCT05556928Registry for Adults With Plasma Cell Disorders (PCD's)
Nagre-recruitObservasyonal na pag-aaral
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 20, 2025 · NCT03717844Mula sa ClinicalTrials.gov, na-kuha noong Set 30, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.